Australian company Emyria (ASX:EMD) has announced interim clinical results from an analysis of its MDMA-assisted therapy for post-traumatic stress disorder program, which commenced in October 2023. …
Emyria announces interim clinical trial results for PTSD program
September 2, 2024 Australian Biotech
Latest Video
New Stories
-
Patients do not live their condition as aggregated economic models
January 14, 2025 - - Latest News -
Delays were the intended outcome, not an unintended consequence
January 13, 2025 - - Latest News -
Attitudes may have evolved, but the framework they created remains virtually unchanged
January 13, 2025 - - Latest News -
Boehringer Ingelheim's Auckland office leads sustainability in NZ pharma sector
January 10, 2025 - - Latest News -
Companies welcome November PBAC outcomes
December 23, 2024 - - Latest News -
The 'Dispatched' Podcast - 'This draws a line through everything and it's not good'
December 22, 2024 - - Podcast -
'Found irregularities and anomalies in the instruments of delegation from the minister'
December 20, 2024 - - Latest News